Drug Updates

Cannabinoids Show Potential in Pain Management

February 13, 2020 • By Mike Fillon

felipe caparros / shutterstock.com

Copay Accumulator Programs Can Derail Rheumatologic Treatment Plans

February 13, 2020 • By Wendy Ramey, BSPharm, RPh, CSP

FDA Rheumatology Update: New Drug Approvals, Plus Expanded Drug Indications & Safety Concerns

February 12, 2020 • By Susan Bernstein

Remembering Etanercept & the Advent of the Biologic Era

February 10, 2020 • By Robert S. Katz, MD

Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis

February 5, 2020 • By Michele B. Kaufman, PharmD, BCGP

Biologic Spending & Price Trends

January 28, 2020 • By Arthritis & Rheumatology

Canada & E.U. Approve Upadacitinib for RA

January 28, 2020 • By Michele B. Kaufman, PharmD, BCGP

Denosumab Tied to Infection Risk

January 13, 2020 • By Marilynn Larkin

Novartis, Merck & Allergan Join Those Raising U.S. Drug Prices for 2020

January 7, 2020

Phase 3 Results for Ixekizumab Promising in Patients with Non-Radiographic Axial Spondyloarthritis

January 6, 2020 • By Michele B. Kaufman, PharmD, BCGP

1
2
3
…
99
Next Page »